Loading...
XNASIONS
Market cap5.38bUSD
Jan 08, Last price  
34.10USD
1D
-2.49%
1Q
-10.14%
Jan 2017
-28.71%
Name

Ionis Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:IONS chart
P/E
—
P/S
6.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.33%
Rev. gr., 5y
5.60%
Revenues
788m
+34.18%
42,624,00040,133,00024,532,00069,621,000107,190,000121,600,000108,473,00099,086,000102,049,000147,285,000214,161,000283,703,000346,620,000507,666,000599,674,0001,123,000,000729,000,000810,000,000587,000,000787,647,000
Net income
-366m
L+35.66%
-142,503,000-72,401,000-45,903,000-10,994,000-11,963,000155,066,000-61,251,000-84,801,000-65,478,000-60,644,000-38,984,000-88,278,000-86,556,000-5,970,000273,741,000294,000,000-487,000,000-29,000,000-270,000,000-366,286,000
CFO
-308m
L+12.08%
-101,751,000-61,741,000-53,225,00036,094,000212,031,000-108,441,000-63,593,000-114,801,0001,876,00063,493,0006,285,00021,125,000-112,105,000174,149,000602,888,000345,720,00035,892,00030,799,000-274,370,000-307,513,000
Earnings
Feb 19, 2025

Profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
URL
https://www.ionispharma.com/
IPO date
May 17, 1991
Employees
796
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
787,647
34.18%
587,000
-27.53%
Cost of revenue
1,141,358
998,000
Unusual Expense (Income)
NOPBT
(353,711)
(411,000)
NOPBT Margin
Operating Taxes
32,321
12,000
Tax Rate
NOPAT
(386,032)
(423,000)
Net income
(366,286)
35.66%
(270,000)
831.03%
Dividends
Dividend yield
Proceeds from repurchase of equity
49,442
(4,580)
BB yield
-0.68%
0.09%
Debt
Debt current
53,163
7,535
Long-term debt
2,084,987
1,523,000
Deferred revenue
241,184
288,000
Other long-term liabilities
16,000
Net debt
(236,042)
(496,837)
Cash flow
Cash from operating activities
(307,513)
(274,370)
CAPEX
(23,805)
(20,099)
Cash from investing activities
(214,127)
(262,636)
Cash from financing activities
644,082
(55,295)
FCF
(372,971)
(483,668)
Balance
Cash
2,331,201
1,987,000
Long term investments
42,991
40,372
Excess cash
2,334,810
1,998,022
Stockholders' equity
(1,828,412)
(1,486,963)
Invested Capital
4,423,557
3,710,249
ROIC
ROCE
EV
Common stock shares outstanding
143,190
141,848
Price
50.59
33.94%
37.77
24.12%
Market cap
7,243,982
35.21%
5,357,599
24.85%
EV
7,007,940
4,860,762
EBITDA
(331,213)
(388,895)
EV/EBITDA
Interest
8,122
Interest/NOPBT